| 12.71 -0.08 (-0.63%) | 09-11 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 18.71 | 1-year : | 21.3 |
| Resists | First : | 16.02 | Second : | 18.23 |
| Pivot price | 14.92 |
|||
| Supports | First : | 12.43 | Second : | 10.34 |
| MAs | MA(5) : | 14.18 |
MA(20) : | 14.7 |
| MA(100) : | 12.91  |
MA(250) : | 12.21 |
|
| MACD | MACD : | -0.1 |
Signal : | 0.1 |
| %K %D | K(14,3) : | 16.3 |
D(3) : | 27.6 |
| RSI | RSI(14): 37.4 |
|||
| 52-week | High : | 18.56 | Low : | 7.48 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ BHVN ] has closed above bottom band by 3.3%. Bollinger Bands are 51% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 1 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 13.4 - 13.47 | 13.47 - 13.55 |
| Low: | 12.37 - 12.46 | 12.46 - 12.54 |
| Close: | 12.56 - 12.7 | 12.7 - 12.85 |
Biohaven Ltd., a biopharmaceutical company, focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide. It develops BHV-1300, which is in Phase 2 clinical trial to treat Graves' disease and rheumatoid arthritis; BHV-1400 that is in Phase 2 clinical trial for treating IgA nephropathy; BHV-1600, which is in Phase 1 clinical trial for the treatment of peripartum cardiomyopathy; BHV-8000 that is in Phase 3 clinical trial for treating Parkinson's disease; Opakalim, which is in Phase 3 clinical trial for the treatment of focal epilepsy; BHV-2100 that is in Phase 2 clinical trial for the treatment of pain disorders; and BHV-2000, which is in Phase 2 clinical trial for treating obesity. The company is also developing BHV-1510 that is in Phase 2 clinical trial for the treatment of advanced or metastatic epithelial tumors; and BHV-1530, which is in Phase 2 clinical trial for treating urothelial cancer and other tumors. In addition, its preclinical product pipeline includes BHV-1310 for treating myasthenia gravis; BHV-1320 for treating immune mediated-diseases; BHV-1450 for treating Pemphigus, MuSK MG, and LGI-1 Encephalitis; BHV-1420 for treating membranous nephropathy; BHV-1440 for treating Graves' disease and TED; BHV-6500 for treating type 1 diabetes; BHV-1490 for treating IgM neuropathy and Waldenstrom's; BHV-8100 for treating neurodegenerative diseases; and BHV-1955 for treating tinnitus. The company was formerly known as Biohaven Research Ltd. and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.
Fri, 11 Sep 2026
Biohaven Faces New Securities Investigation - stl.news
Fri, 11 Sep 2026
Biohaven Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Biohaven (BHVN) - PR Newswire
Thu, 10 Sep 2026
Biohaven: The Hold Isn't The Problem (Rating Downgrade) (NYSE:BHVN) - Seeking Alpha
Thu, 10 Sep 2026
BHVN Stock Slips As Kv7 Deal Seen As Stopgap Move - StocksToTrade
Thu, 10 Sep 2026
BHVN Stock Slips As SK Deal Seen As Buying Time - timothysykes.com
Thu, 10 Sep 2026
Why Is Biohaven Stock Tumbling Today? - Biohaven (NYSE:BHVN) - Benzinga
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 151 (M) |
| Shares Float | 117 (M) |
| Held by Insiders | 11.1 (%) |
| Held by Institutions | 96.6 (%) |
| Shares Short | 17,820 (K) |
| Shares Short P.Month | 19,350 (K) |
| EPS | -4.56 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.07 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -72 % |
| Return on Equity (ttm) | -799.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -3.45 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -511 (M) |
| Levered Free Cash Flow | -256 (M) |
| PE Ratio | -2.8 |
| PEG Ratio | 0 |
| Price to Book value | 158.87 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|